NDAORALTABLET
Approved
May 2014
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Data completeness
3/8 — Basic
Drug data last refreshed 8m ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZONTIVITY (vorapaxar sulfate) is an oral protease-activated receptor-1 (PAR-1) antagonist approved in 2014 for reducing thrombotic cardiovascular events in patients with stable coronary artery disease or peripheral artery disease. It works by inhibiting platelet activation through a novel mechanism distinct from traditional antiplatelet agents.
$0.051MPart D
LOE ApproachingDeclining
1.5 years to LOEMinimal commercial momentum with near-LOE status suggests a contracting team focused on managed decline rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
Patent cliff in ~2 years — expect lifecycle management and generic defense hiring
Worked on ZONTIVITY at Passkey Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.